Work Here?
Genesis Molecular AI
Work Here?
AI-driven drug discovery platform for pharma
Genesis Molecular AI
Work Here?
AI-driven drug discovery platform for pharma
Overview
Genesis Molecular AI uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. It combines 3D spatial graph modeling and advanced molecular simulation to generate and evaluate potential drug candidates and to uncover novel protein targets. The platform translates complex molecular data into actionable candidates by representing molecules in 3D graphs and running simulations to predict how they bind to target proteins, helping partners identify promising therapies. The company differentiates itself by integrating 3D spatial graph modeling with detailed molecular simulations to explore untapped chemical space and novel targets, and by focusing on business-to-business partnerships with pharma and biotech companies. Its goal is to accelerate drug discovery for partners by delivering AI-generated candidates and enabling faster progression from target to therapy.
About Genesis Molecular AI
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$400.1M
Headquarters
Burlingame, California
Founded
2019
Get referred to Genesis Molecular AI
See people who can refer or advise you
Simplify's Take
What believers are saying
- Incyte expanded Genesis on May 20, 2026 with $120 million upfront and equity.
- The deal can exceed $1 billion across five targets, plus royalties and recurring compute funding.
- Genesis’ May 20, 2026 Pearl release beat OpenBind benchmarks, strengthening partnering leverage.
What critics are saying
- Incyte holds exclusive commercialization rights, so Genesis depends on partners for product revenue.
- No approved drug exists; if GEMS misses preclinical wins in 2026, fundraising weakens.
- AI-drug-discovery competitors like Isomorphic Labs compress pricing, and Genesis risks becoming a services vendor.
What makes Genesis Molecular AI unique
- Genesis Molecular AI pairs physics-based GEMS with foundation models and Pearl, unveiled May 20, 2026.
- Incyte’s May 20, 2026 collaboration trains GEMS on proprietary experimental data, a rare moat.
- Sergey Edunov joined in November 2025, bringing Meta Llama-scale model-building expertise.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$400.1M
Above
Industry Average
Funded Over
4 Rounds
Andreessen Horowitz
Menlo VenturesBenefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Parental Leave
Disability Insurance
Life Insurance
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -3%2 year growth
↓ -1%Incyte and Genesis expand molecular AI collaboration to accelerate drug discovery
Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard? Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform. Genesis Molecular AI, the foundation model-driven drug design firm formerly known as Genesis Therapeutics, has appointed Sergey Edunov as Senior Vice President of Foundation Models. The executive hire marks a strategic inflection point as the company prepares to scale its GEMS platform and unveil new generative model research at the NeurIPS 2025 conference. Sergey Edunov is best known for his leadership role in developing Meta Platforms' Llama 2 and Llama 3 large language models. He brings over two decades of software engineering and AI research experience, having previously served as Senior Director of AI Research in Meta's generative AI division. His arrival at Genesis Molecular AI signals the firm's ambition to compete at the highest levels of foundation model development applied to molecular design.
Genesis Therapeutics has successfully raised a $52 million A round to advance its AI-focused drug discovery mission. The company employs a novel simulation approach and a cross-disciplinary team to efficiently explore the vast array of potential medicinal molecules.
Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.
Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
Genesis Molecular AI is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Genesis Molecular AI
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$400.1M
Headquarters
Burlingame, California
Founded
2019
Genesis Molecular AI is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today